End Stage Renal Disease, Heart Failure
Conditions
Interventions
experimental group:sacubarb/valsartan taken
Sponsors
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Male or female patients aged 18-80 years; 2. Qualitative diagnosis: chronic renal failure patients, glomerular filtration rate 40%, but abnormal ventricular diastolic function (according to PARAGON-HF study, E / E 'value, septal and lateral wall e' velocity, left atrial maximum volume index (LAMVI), and maximum tricuspid regurgitation velocity were analyzed). Echocardiography was performed by two doctors with more than 5 years of ultrasound experience in the Department of Cardiology, Peking Union Medical College Hospital. The ultrasound data were saved for follow-up analysis. 5. Patients or their family members can understand the study protocol and are willing to participate in the study and provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with malignant tumor or expected survival period is less than 6 months; 2. Severe liver disease; 3. Surgery is needed in the near future; 4. Pregnant or lactating women; women of childbearing age with positive or no pregnancy test at baseline. Postmenopausal women must be postmenopausal for at least 12 months; 5. Echocardiography showed new ventricular wall motion abnormalities, or symptoms of unstable angina pectoris, and ECG has the corresponding prompt. Or patients with myocardial infarction or unstable angina pectoris within 1 month according to clinical judgment; 6. Allergic to or contraindication to the drug components of sakubatro or valsartan; 7. Serum potassium > 5.4mmol/l; 8. Blood vessel edema happened after ACEI or ARB drugs used in the past; 9. The patients or their families can not understand and accept the conditions and objectives of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| E/e' value;E'velocity of interventricular septum and lateral wall;LAMVI;Maximum tricuspid regurgitation velocity; | — |
Countries
China
Contacts
Public ContactXuemei Li, Zhicheng Jing
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed